Trial · NCT07522151
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
NCT07522151, Phase 3, Recruiting, Shanghai Shengdi Pharmaceutical Co., Ltd
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer. Trials, record NCT07522151. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07522151
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
- NCT number
- NCT07522151
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 874 participants, estimated
- Lead sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
- Conditions
- Locally Advanced Gastric or Gastroesophageal Junction Cancer
- Interventions
- Adebrelimab plus S-1 and oxaliplatin, Adebrelimab blank preparation plus S-1 and oxaliplatin.
- First posted
- 2026-04-13
- Last updated
- 2026-05-13
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Investigator-assessed EFS | About 8 years | Assessments BY INVESTIGATORS |
| Secondary | Complete response (pCR) rate as assessed by the Pathology Review Committee (PRC) | About 3 years | Complete remission (pCR) rates after surgery |
| Secondary | Rate of pathologically significant response (MPR) as assessed by the Pathology Review Committee (PRC) | About 3 years | Pathologically significant response (MPR) rate after surgery |
| Secondary | EFS as assessed by an independent review committee (IRC) | About 8 years | Independent Review Committee (IRC) evaluation |
| Secondary | DFS, as assessed by investigator /IRC | About 8 years | Investigator /IRC assessment |
| Secondary | pCR rate by central pathological evaluation | About 3 years | Central pathological evaluation was studied |
| Secondary | R0 resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups | About 8 years | Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator |
| Secondary | D2 radical resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups | About 8 years | Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator |
| Secondary | objective response rate (ORR) of neoadjuvant therapy evaluated by investigators in different treatment groups | About 8 years | Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator |
| Secondary | The incidence of adverse events (AE) were evaluated according to NCI-CTCAE 6.0 | About 4 years | NCI-CTCAE 6.0 was used for evaluation |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07522151
GET https://conductscience.org/api/trials/v1/NCT07522151/registered